Clinical trial NCT06747455: BCG for Therapeutic Use Phase Ⅲ Clinical Trial
Official title: A Randomized, Double-blind, Active-controlled, Multicenter Phase III Clinical Trial Evaluating the Efficacy and Safety of Therapeutic BCG for the Prevention of Postoperative Recurrence of Non-muscle-invasive Bladder Cancer in People Aged 18 Years and Older
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE3
Conditions: BCG
Keywords: Bacillus Calmette-Guérin for treatment
Bladder cancer.
Lead sponsor: Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2024-12-24
Enrollment: 438
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Research topic: A randomized, double-blind, active-controlled, multicenter phase III clinical trial evaluating the efficacy and safety of therapeutic BCG for the prevention of postoperative recurrence of non-muscle-invasive bladder cancer in people aged 18 years and older.

The name of the drug: Bacillus Calmette-Guérin for treatment(BCG). Clinical indications: It is used for the treatment of bladder carcinoma in situ and the prevention of recurrence, and for the prevention of recurrence of bladder papilloma after transurethral resection in Ta or T1 stage. This product is not used for papillomas beyond the T1 stage.

Study population: Patients aged 18 years and above with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) who have undergone transurethral bladder tumor resection.

Objectives: Primary Objectives: To assess the effectiveness of BCG for therapeutic use in the adjuvant treatment of intermediate- and high-risk NMIBC after transurethral resection of bladder tumors. Secondary Purpose: To assess the safety of the therapeutic BCG vaccine in the adjuvant treatment of intermediate- and high-risk NMIBC after transurethral resection of bladder tumors. Other purposes: To assess the pharmacodynamic (PD) profile of BCG for therapeutic use in the adjuvant treatment of intermediate- and high-risk NMIBC after transurethral resection of bladder tumors.

Study design: This study adopts a randomized, double-blind, active-controlled, multi-center trial design, including three phases: screening period, treatment period and follow-up period. In this study, 438 subjects will be randomly assigned to the experimental group and the control group in a 1:1 ratio, with 219 patients in both the experimental group and the control group, and stratified according to the baseline risk level (high-risk/intermediate-risk) and whether or not to perform urine PD sample collection (yes/no).

Detailed description: Research topic: A randomized, double-blind, active-controlled, multicenter phase III clinical trial evaluating the efficacy and safety of therapeutic BCG for the prevention of postoperative recurrence of non-muscle-invasive bladder cancer in people aged 18 years and older.

Study endpoints: Endpoint efficacy: Main efficacy measures: 1-year recurrence-free survival rate (1-year RFS%): To assess the proportion of participants who are relapse-free or die from randomization up to 1 year, whichever occurs first. Secondary efficacy endpoint: 2-year recurrence-free survival rate (2-year RFS%): Assessing the proportion of subjects who have not experienced recurrence or death (whichever occurs first) from randomization until 2 years. 1-year progression-free survival rate (1-year PFS%): Assessing the proportion of subjects experiencing tumor progression or death from randomization until 1 year. The 2-year progression-free survival rate (2-year PFS%) assesses the proportion of subjects experiencing tumor progression or death from the time of randomization until 2 years. Security endpoint: Incidence of all AEs and SAEs; Any clinically significant abnormalities in vital signs or physical examinations during the trial period; Any clinically significant abnormalities found during the trial period laboratory examinations or electrocardiogram examinations. Other destinations: Changes in the levels of interleukin 2 (IL-2), interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-12 (IL-12), interferon γ (IFN-γ), and tumor necrosis factor (TNF) in urine excreted at 4 h±1 h, 8 h±, 2 h, and 24 h±3 h after the 1st (V1), 6th (V6), 9th (V9), and 10th (V10) administration.

Overall design: This study adopts a randomized, double-blind, positive-controlled, multicenter trial design, including three phases: screening, treatment, and follow-up. A total of 438 subjects will be enrolled in this study, with a 1:1 random allocation to the experimental group and the control group, both consisting of 219 subjects. Stratification will be based on baseline risk level (high risk/medium risk) and whether urine PD samples are collected (yes/no). Selection period: During the first 28 days prior to administration, the subjects will undergo eligibility confirmation for enrollment. Subjects who meet the eligibility criteria will enter the treatment phase and receive the investigational drug infusion.

Treatment period (Year 1): The treatment period includes the induction phase, consolidation phase, and maintenance phase.

After undergoing transurethral bladder tumor resection, eligible subjects are screened and randomly assigned to the study. Within 2 to 12 weeks after surgery, subjects receive bladder instillation therapy: once a week during the induction phase for a total of 6 times, once every two weeks during the consolidation phase for a total of 3 times, and once every 4 weeks during the maintenance phase for a total of 19 times, continuing until 1 year after surgery.

During the first year of the study, subjects undergo imaging examinations every 12 months, urine cytology examinations every 3 months, and cystoscopy. If a subject shows positive results in either cystoscopy or urine cytology, the researcher may decide to perform additional imaging examinations.

Follow-up period (Year 2): After completing one year of intravesical therapy, or if treatment is discontinued early without tumor recurrence or progression, or if the subject continues treatment into the second year, participants meeting the above criteria should undergo imaging examinations every 12 months, urine cytology and cystoscopy every 3 months, until tumor recurrence or progression, withdrawal of informed consent, loss to follow-up, study termination by the sponsor, initiation of new anti-tumor treatment, or death (whichever occurs first). If a participant has a positive cystoscopy or urine cytology result, the investigator may decide to perform imaging examinations.

Eligibility criteria: Inclusion Criteria:

* 1. Age≥ 18 years old, male or female;
* 2. According to the Guidelines for the Diagnosis and Treatment of Bladder Cancer (2022 Edition), the initial histological diagnosis of intermediate- and high-risk non-muscle-invasive urothelial carcinoma of the bladder (T1, Ta or Tis) and the need for BCG bladder infusion adjuvant therapy is evaluated;
* 3. Patients undergoing transurethral bladder tumor resection need to meet the requirements of all tumors to have no visible tumors after surgery. This study can also enroll patients who need a second electroresection, and subjects who meet the criteria for a second resection should undergo a second resection, which should be included in the study after a comprehensive evaluation of the two pathological results (BCG perfusion for treatment should be carried out within 2\~12 weeks after surgery, cystoscopy should be added more than 4 weeks after surgery to ensure that there is no visible tumor after surgery, and the subjects who underwent secondary resection should be calculated based on the postoperative time of the second electroresection); Note: The criteria for the second resection: (1) the first TURBt is insufficient; (2) the first electrosection of non-myometrial tissue specimens; (3) T1 tumors; (4) High-grade (G3) tumors, except for carcinoma in situ. The second resection is recommended to be performed within 2-6 weeks after the first resection, and no other perfusion therapy is allowed except for the bladder infusion chemotherapy drugs immediately after the first and second resection;
* 4. Eastern Cooperative Oncology Group (ECOG) score (see Appendix 1 for details): 0\~2 points;
* 5. At screening, clinical laboratory tests meet the following characteristics:

  1. Blood routine: no use of hematopoietic growth factors or blood transfusion support within 14 days before randomization, including: absolute neutrophil count (ANC) ≥1500/mm\^3 or ≥1.5×10\^9/L; Platelets≥ 100000/mm\^3 or 100×10\^9/L; Hemoglobin ≥ 9 g/dL.
  2. Liver function: total bilirubin ≤ 1.5× upper limit of normal range (ULN), subjects with Gilbert's syndrome require total bilirubin \<3×ULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5×ULN.
  3. Renal function: defined as creatinine clearance estimated according to the Cockcroft Gault formula (Appendix 2) ≥ 30mL/min;
  4. Coagulation function: activated partial thromboplastin time (APTT) ≤ 1.5×ULN, and the international normalized ratio (INR) ≤ 1.5×ULN.
* 6. Voluntarily participate in this trial, with full informed consent and signed written informed consent.

Exclusion Criteria:

* 1. Those who have immunodeficiency or damage (such as AIDS patients), are using immunosuppressive drugs, steroid hormones, etc., which may cause systemic BCG disease reaction (other hormones such as patients who are given corresponding hormone therapy after thyroid/adrenal resection can be enrolled);
* 2. Those who are allergic to BCG and its excipients;
* 3. Active tuberculosis, those who are receiving or have received anti-tuberculosis treatment within 6 months before screening;
* 4. Patients with severe cardiovascular and cerebrovascular, liver, lung, and kidney diseases at the time of screening;
* 5. Patients with other genitourinary tumors or other organ tumors at the time of screening, and no obvious tumor recurrence or progression in the past 3 years, and stable condition can be considered for inclusion, such as basal cell or squamous cell skin cancer that has been adequately treated; carcinoma in situ of the breast or cervix; Low-grade prostate cancer that is monitored without any planned therapeutic intervention (e.g., surgery, radiotherapy, or castration); and other concurrent malignancies that in the opinion of the investigator have a very low likelihood of progression;
* 6. Patients with histologically confirmed muscle-invasive, locally advanced, unresectable or metastatic urothelial carcinoma or a history of this disease (i.e., ≥ T2);
* 7. Those who have received any BCG treatment for NMIBC in the past;
* 8. Those who know or suspect that abnormal conditions such as bladder perforation occur during surgery;
* 9. Those who suspect that the surgical wound has not healed or the urinary tract mucosa is damaged;
* 10. Those who have been assessed by the investigator to be accompanied by cystitis (such as urinary frequency, urgency, dysuria, etc.), or have received other bladder infusion drugs and have severe bladder irritation, which is expected to affect the evaluation of this study;
* 11. Those who have received chemotherapy, radiotherapy, and immunotherapy within 4 weeks before the first dose (except for intravesical chemotherapy immediately after surgery);
* 12. Pregnant or lactating women;
* 13. Those who cannot guarantee effective contraception during the trial period to 6 months after the last dose;
* 14. Received treatment with other clinical trial drugs (except placebo) or clinical trial devices within 3 months before the first dose;
* 15. Those who have a history of alcoholism, drug abuse or drug abuse within 6 months before screening;
* 16. Presence of any of the following: positive human immunodeficiency virus (HIV) antibody, positive syphilis-specific antibody, active hepatitis B (hepatitis B surface antigen (HBsAg) positive and hepatitis B virus deoxyribonucleic acid (DNA) copy number ≥200 IU/mL or 1000 copies/mL), hepatitis C virus (HCV) antibody positive and HCV virus copy number higher than the upper limit of normal in the research center≥ 10\^3/mL;
* 17. Any condition that, in the opinion of the investigator, may increase the risk of the subject or interfere with the performance of the clinical trial.

Primary outcomes:
measure: 1-year RFS%
timeFrame: Up to 1 year after randomization
measure: Safety endpoints
timeFrame: 30 days after the last dose
measure: Safety endpoints
timeFrame: 30 days after the last dose
measure: Safety endpoints
timeFrame: 30 days after the last dose
measure: Safety endpoints
timeFrame: 30 days after the last dose
measure: Safety endpoints
timeFrame: 30 days after the last dose
measure: Safety endpoints
timeFrame: 30 days after the last dose
Secondary outcomes:
measure: 2-years RFS%
timeFrame: Up to 2 years after randomization
measure: 1-year PFS%
timeFrame: Up to 1 year after randomization
measure: 2-years PFS%
timeFrame: Up to 2 years after randomization
Other outcomes:
measure: To evaluate the PD characteristics of the therapeutic BCG vaccine for adjuvant therapy after transurethral resection of intermediate- and high-risk NMIBC
timeFrame: The 1st , 6th , 9th and 10th (V10) doses were last excreted before administration, 4 h±1 h, 8 h± 2 h, and 24 h±3 h after administration
measure: To evaluate the PD characteristics of the therapeutic BCG vaccine for adjuvant therapy after transurethral resection of intermediate- and high-risk NMIBC
timeFrame: The 1st , 6th , 9th and 10th (V10) doses were last excreted before administration, 4 h±1 h, 8 h± 2 h, and 24 h±3 h after administration
measure: To evaluate the PD characteristics of the therapeutic BCG vaccine for adjuvant therapy after transurethral resection of intermediate- and high-risk NMIBC
timeFrame: The 1st , 6th , 9th and 10th (V10) doses were last excreted before administration, 4 h±1 h, 8 h± 2 h, and 24 h±3 h after administration
measure: To evaluate the PD characteristics of the therapeutic BCG vaccine for adjuvant therapy after transurethral resection of intermediate- and high-risk NMIBC
timeFrame: The 1st , 6th , 9th and 10th (V10) doses were last excreted before administration, 4 h±1 h, 8 h± 2 h, and 24 h±3 h after administration
measure: To evaluate the PD characteristics of the therapeutic BCG vaccine for adjuvant therapy after transurethral resection of intermediate- and high-risk NMIBC
timeFrame: The 1st , 6th , 9th and 10th (V10) doses were last excreted before administration, 4 h±1 h, 8 h± 2 h, and 24 h±3 h after administration
measure: To evaluate the PD characteristics of the therapeutic BCG vaccine for adjuvant therapy after transurethral resection of intermediate- and high-risk NMIBC
timeFrame: The 1st , 6th , 9th and 10th (V10) doses were last excreted before administration, 4 h±1 h, 8 h± 2 h, and 24 h±3 h after administration
Locations:
city: Bengbu
country: China
facility: The First Affiliated Hospital of Bengbu Medical College
state: Anhui
city: Hefei
country: China
facility: The First Affiliated Hospital of USTC
state: Anhui
city: Beijing
country: China
facility: Beijing Chaoyang Hospital Affiliated to Capital Medical University
state: Beijing
city: Beijing
country: China
facility: Peking University First Hospital
state: Beijing
city: Beijing
country: China
facility: Beijing Cancer Hospital
state: Beijing
city: Chongqing
country: China
facility: The First Affiliated Hospital of Army Medical University
state: Chongqing
city: Chongqing
country: China
facility: Chongqing University Cancer Hospital
state: Chongqing
city: Fuzhou
country: China
facility: Union Hospital Affiliated to Fujian Medical University
state: Fujian
city: Guangzhou
country: China
facility: Sun Yat-sen University Cancer Hospital
state: Guangdong
city: Guangzhou
country: China
facility: The First Affiliated Hospital of Guangzhou Medical University
state: Guangdong
city: Nanning
country: China
facility: Cancer Hospital Affiliated to Guangxi Medical University
state: Guangxi Zhuang Autonomous Region
city: Shijiazhuang
country: China
facility: The Second Hospital of Hebei Medical University
state: Hebei
city: Xingtai
country: China
facility: Xingtai People's Hospital
state: Hebei
city: Haerbin
country: China
facility: Cancer Hospital Affiliated to Harbin Medical University
state: Heilongjiang
city: Zhengzhou
country: China
facility: The First Affiliated Hospital of Zhengzhou University
state: Henan
city: Changsha
country: China
facility: Hunan Provincial Cancer Hospital
state: Hunan
city: Hohhot
country: China
facility: People's Hospital of Inner Mongolia Autonomous Region
state: Inner Mongolia
city: Nanjing
country: China
facility: Drum Tower Hospital Affiliated to Nanjing University School of Medicine
state: Jiangsu
city: Nanjing
country: China
facility: Jiangsu Provincial Cancer Hospital
state: Jiangsu
city: Nanchang
country: China
facility: The First Affiliated Hospital of Nanchang University
state: Jiangxi
city: Suzhou
country: China
facility: The Second Affiliated Hospital of Soochow University
state: Jiangxsu
city: Changchun
country: China
facility: Jilin Provincial People's Hospital
state: Jilin
city: Shenyang
country: China
facility: The First Affiliated Hospital of China Medical University
state: Liaoning
city: Jinan
country: China
facility: Qilu Hospital of Shandong University
state: Shandong
city: Qingdao
country: China
facility: The Affiliated Hospital of Qingdao University
state: Shandong
city: Yantai
country: China
facility: Yantai Yuhuangding Hospital
state: Shandong
city: Shanghai
country: China
facility: Fudan University Shanghai Cancer Center
state: Shanghai
city: Shanghai
country: China
facility: Huadong Hospital Affiliated to Fudan University
state: Shanghai
city: Shanghai
country: China
facility: Shanghai Changhai Hospital
state: Shanghai
city: Taiyuan
country: China
facility: The First Hospital of Shanxi Medical University
state: Shanxi
city: Xian
country: China
facility: The First Affiliated Hospital of Xi'an Jiaotong University
state: Shanxi
city: Chengdu
country: China
facility: West China Hospital, Sichuan University
state: Sichuan
city: Tianjin
country: China
facility: The Second Hospital of Tianjin Medical University
state: Tianjin
city: Kunming
country: China
facility: Yunnan Cancer Hospital
state: Yunnan
city: Hangzhou
country: China
facility: The Second Affiliated Hospital of Zhejiang University School of Medicine
state: Zhejiang
city: Wenzhou
country: China
facility: The First Affiliated Hospital of Wenzhou Medical University
state: Zhejiang
Study officials:
References: